glp 1 powerpoint presentation Glucagon‐like peptide agonists: A prospective review - Mariam - 2024 - Endocrinology, Diabetes & Metabolism PPT - Updates on GLP-1

The archive includes surveys conducted in partnership with the Health Research and Education Trust through 2017 and a small business supplement of the 1998 survey conducted by KFF

Wu X, Han T, Gao J, Zhang Y, Zhao S, Sun R, et al

Member notification letters went out between August and November

No long-term contracts mean you can adjust your commitment based on results and satisfaction

Highlights from study findings include: 751 individuals participated in the study The mean percent change in weight at week 72 was -20.2% for those taking tirzepatide and -13.7% for those taking semaglutide The most common side effects were gastrointestinal A 2025 real-world study of over 2,300 patients treated at an academic obesity clinic also showed meaningful weight loss, especially among those who stayed on therapy for at least a year